Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

This publication has 28 references indexed in Scilit:

• Oral combination therapy for type 2 diabetes
  Diabetes/Metabolism Research and Reviews, 2002
• Clinical evidence of thiazolidinedione‐induced improvement of pancreatic β‐cell function in patients with type 2 diabetes mellitus
  Diabetes, Obesity and Metabolism, 2002
• Improved Glycemic Control and Enhanced Insulin Sensitivity in Type 2 Diabetic Subjects Treated With Pioglitazone
  Diabetes Care, 2001
• Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
  Diabetes Care, 2000
• Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49)
  JAMA, 1999
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
  The Lancet, 1998
• PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
  Diabetes, 1998
• Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator Activated Receptors γ1 and γ2
  Biochemical and Biophysical Research Communications, 1996
• Oral Hypoglycemic Agents
  New England Journal of Medicine, 1989
• Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man
  Diabetologia, 1985